Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

Copart's relentless compounding potential and long-term growth prospects make it a valuable investment. Click to find out why ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

根据美国证券交易委员会的Form 4文件显示，总部位于特拉华州的投资公司Focused Compounding Fund, LP近期大举增持Parks America, Inc. (OTC: PRKA )普通股。该基金以每股0.35美元的价格购入867,514股，总投资额约为303,629美元。目前该股票交易价格为0.41美元，根据 InvestingPro 的公允价值分析，当前估值偏高。

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...